Argenica Therapeutics (ASX:AGN) said that its ARG-007 neuroprotective peptide drug candidate "significantly" reduced damage to brain cells caused by moderate traumatic brain injury in a preclinical rat study, according to a Tuesday Australian bourse filing.
The study assessed ARG-007 regarding the reduction of axonal injury and neuroinflammation seen following moderate traumatic brain injury and resulting behavioral outcomes.
It was found to protect brain cells in the injured brain by reducing axonal injury following injury, as measured by key axonal injury biomarkers neurofilament heavy protein and amyloid precursor protein.
The animals treated with the candidate also showed signs of improvement in a motor function test as well as a significant reduction in weight loss.
The data verifies data received from previous studies.
The firm's shares rose past 1% in recent trading on Tuesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。